Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

Genenta Announces Nomination of Mark A. Sirgo as Chair

GlobeNewswire April 27, 2022

Collegium Completes the Acquisition of BDSI

GlobeNewswire March 22, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SJI, OBNK, CTXS, BDSI

PR Newswire March 1, 2022

SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, MIME, VRS, and EPAY Shareholders About Its Ongoing Investigations

PR Newswire February 28, 2022

BioDelivery Sciences International Announces ELYXYB(TM) is Now Available in the U.S. for the Acute Treatment of Migraine

GlobeNewswire February 24, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FLOW, BDSI, CHWA, DNAA, CCMP

PR Newswire February 22, 2022

SHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, FTSI, CCMP, and FLOW Shareholders About Its Ongoing Investigations

PR Newswire February 21, 2022

BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences International, Inc. - BDSI

PR Newswire February 16, 2022

Moore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law Firm

PR Newswire February 15, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of BioDelivery Sciences International, Inc. Buyout

Newsfile February 15, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BDSI, ZWS, NLIT, SPK, SWAG

PR Newswire February 15, 2022

Shareholder Alert: The M&A Class Action Firm is Investigating the Merger of BDSI, ZWS, RRD, QDEL, RC, TACO

PR Newswire February 14, 2022

BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders

Business Wire February 14, 2022

Shareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price in its transaction with Collegium.

PR Newswire February 14, 2022

Collegium to Acquire BioDelivery Sciences in an All-Cash Deal

GlobeNewswire February 14, 2022

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance

GlobeNewswire January 20, 2022

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032

GlobeNewswire December 20, 2021

BioDelivery Sciences Reports Solid Third Quarter 2021 Results

GlobeNewswire November 3, 2021

BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer

GlobeNewswire October 21, 2021

BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021

GlobeNewswire October 20, 2021